Zydus Lifesciences (ZYDUSLIFE) — Financial Results

Zydus Lifesciences reported FY25 consolidated revenue of ₹232.4 billion, up 19% YoY, driven by 11% growth in Indian formulations and double-digit US generics expansion. Net profit reached ₹47.5 billion, up 22% YoY, with EBITDA margin improving to 30.4% (+290 bps). Quarterly revenue rose 24% QoQ to ₹65.3 billion, supporting strong margin gains from cost controls and pricing. Strategic moves include acquiring Naturell (India) for nutrition and Amplitude Surgical for medtech, while advancing FDA-approved ALS drug Usnoflast and a bivalent TCV vaccine. Mirabegron litigation remains manageable through FY26, and Sitagliptin exceeds expectations under a 5-year national contract. The company projects double-digit domestic growth by FY26, though Revlimid pressure and R&D investments may temper FY26 margins below 26% EBITDA guidance.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"How does this financial results affect Zydus Lifesciences Limited's outlook?" "What did Zydus Lifesciences Limited announce on 27 May 2025?" "Is this positive or negative for ZYDUSLIFE?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 27 May 2025

TATAPOWER Tata Power Company Limited Corporate Action AXISBANK Axis Bank Limited Corporate Action TCS Tata Consultancy Services Limited Annual Report TATASTEEL Tata Steel Limited Announcement TCS Tata Consultancy Services Limited Annual Report COALINDIA Coal India Limited Offer Document

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.